Portal de Periódicos da CAPES

A Synthetic Peptide from HIV-1 gp41 Is a Potent Inhibitor of Virus-Mediated Cell—Cell Fusion

1993; Mary Ann Liebert, Inc.; Volume: 9; Issue: 11 Linguagem: Inglês

10.1089/aid.1993.9.1051

1931-8405

Carl Wild, Teresa Greenwell, Thomas J. Matthews,

Influenza Virus Research Studies

AIDS Research and Human RetrovirusesVol. 9, No. 11 A Synthetic Peptide from HIV-1 gp41 Is a Potent Inhibitor of Virus-Mediated Cell—Cell FusionCarl Wild, Teresa Greenwell, and Thomas MatthewsCarl Wild, Teresa Greenwell, and Thomas MatthewsPublished Online:16 Mar 2009https://doi.org/10.1089/aid.1993.9.1051AboutSectionsPDF/EPUB ToolsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail FiguresReferencesRelatedDetailsCited ByNanomolar inhibition of SARS-CoV-2 infection by an unmodified peptide targeting the prehairpin intermediate of the spike protein19 September 2022 | Proceedings of the National Academy of Sciences, Vol. 119, No. 40Viral informatics: bioinformatics-based solution for managing viral infections10 August 2022 | Briefings in Bioinformatics, Vol. 23, No. 5Bioactive Antimicrobial Peptides: A New Weapon to Counteract Zoonosis7 August 2022 | Microorganisms, Vol. 10, No. 8Novel Bent Conformation of CD4 Induced by HIV-1 Inhibitor Indirectly Prevents Productive Viral AttachmentJournal of Molecular Biology, Vol. 434, No. 2Prestimulation of CD2 confers resistance to HIV-1 latent infection in blood resting CD4 T cellsiScience, Vol. 24, No. 11Designing Self-Inhibitory fusion peptide analogous to viral spike protein against novel severe acute respiratory syndrome (SARS-CoV-2)11 August 2021 | Journal of Biomolecular Structure and Dynamics, Vol. 26A Derivative of the D5 Monoclonal Antibody That Targets the gp41 N-Heptad Repeat of HIV-1 with Broad Tier-2-Neutralizing ActivityJournal of Virology, Vol. 95, No. 15Targeting Viral Surface Proteins through Structure-Based Design8 July 2021 | Viruses, Vol. 13, No. 7Potential "biopeptidal" therapeutics for severe respiratory syndrome coronaviruses: a review of antiviral peptides, viral mechanisms, and prospective needs19 April 2021 | Applied Microbiology and Biotechnology, Vol. 105, No. 9Trends in peptide drug discovery3 February 2021 | Nature Reviews Drug Discovery, Vol. 20, No. 4Trends and strategies to combat viral infections: A review on FDA approved antiviral drugsInternational Journal of Biological Macromolecules, Vol. 356Structural Insights to Human Immunodeficiency Virus (HIV-1) Targets and Their Inhibition14 July 2021Triterpenoid-Mediated Inhibition of Virus–Host Interaction: Is Now the Time for Discovering Viral Entry/Release Inhibitors from Nature?17 November 2020 | Journal of Medicinal Chemistry, Vol. 63, No. 24In silico design of antiviral peptides targeting the spike protein of SARS-CoV-2Peptides, Vol. 130Discovery and Development of Anti-HIV Therapeutic Agents: Progress Towards Improved HIV MedicationCurrent Topics in Medicinal Chemistry, Vol. 19, No. 18Transdermal Delivery of Enfuvirtide in a Porcine Model Using a Low-Frequency, Low-Power Ultrasound Transducer PatchUltrasound in Medicine & Biology, Vol. 45, No. 2Potent MERS-CoV Fusion Inhibitory Peptides Identified from HR2 Domain in Spike Protein of Bat Coronavirus HKU414 January 2019 | Viruses, Vol. 11, No. 1From Computers to Bedside: Computational Chemistry Contributing to FDA Approval21 December 2018Folding Molecular Dynamics Simulation of a gp41-Derived Peptide Reconcile Divergent Structure Determinations2 November 2018 | ACS Omega, Vol. 3, No. 11Sulfono-γ-AA modified peptides that inhibit HIV-1 fusion1 January 2018 | Organic & Biomolecular Chemistry, Vol. 16, No. 42HIV-1 inhibitory properties of eCD4-Igmim2 determined using an Env-mediated membrane fusion assay25 October 2018 | PLOS ONE, Vol. 13, No. 10Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency VirusJournal of Virology, Vol. 92, No. 20Inhibition of HIV-1 infection by human pegivirus type 1-derived peptides is affected by human pegivirus type 1 genotype and HIV-1 coreceptor tropismAIDS, Vol. 32, No. 14Bioengineered intravaginal isolate of Lactobacillus plantarum expresses algal lectin scytovirin demonstrating anti-HIV-1 activityMicrobial Pathogenesis, Vol. 122A Novel gp41-Binding Adnectin with Potent Anti-HIV Activity Is Highly Synergistic when Linked to a CD4-Binding Adnectin29 June 2018 | Journal of Virology, Vol. 92, No. 14Exceptional potency and structural basis of a T1249-derived lipopeptide fusion inhibitor against HIV-1, HIV-2, and simian immunodeficiency virus7 February 2018 | Journal of Biological Chemistry, Vol. 293, No. 14Phenotypic deficits in the HIV-1 envelope are associated with the maturation of a V2-directed broadly neutralizing antibody lineage25 January 2018 | PLOS Pathogens, Vol. 14, No. 1Conformational-Restricted Cyclic Peptides17 January 2018Peptidomimetics That Mimic the Tertiary Structures of Peptides17 January 2018Vitamin E and Testicular Damage Protection in Highly Active Antiretroviral TherapyBreast milk and in utero transmission of HIV-1 select for envelope variants with unique molecular signatures26 January 2017 | Retrovirology, Vol. 14, No. 1Mutations in the Fusion Protein of Measles Virus That Confer Resistance to the Membrane Fusion Inhibitors Carbobenzoxy- d -Phe- l -Phe-Gly and 4-Nitro-2-Phenylacetyl Amino-BenzamideJournal of Virology, Vol. 91, No. 23In situ depot formation of anti-HIV fusion-inhibitor peptide in recombinant protein polymer hydrogelActa Biomaterialia, Vol. 64Recent advances in the development of antiviral therapeutics for Rift Valley fever virus infectionFuture Virology, Vol. 12, No. 11Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-62652921 August 2017 | Nature Chemical Biology, Vol. 13, No. 10Structure-based identification of inhibitors targeting obstruction of the HIVgp41 N-heptad repeat trimerBioorganic & Medicinal Chemistry Letters, Vol. 27, No. 14Predicting HIV-1 transmission and antibody neutralization efficacy in vivo from stoichiometric parameters4 May 2017 | PLOS Pathogens, Vol. 13, No. 5Cell-Mediated Immunity to Target the Persistent Human Immunodeficiency Virus Reservoir28 April 2017 | The Journal of Infectious Diseases, Vol. 215, No. suppl_3Site-Specific Polymer Attachment to HR2 Peptide Fusion Inhibitors against HIV-1 Decreases Binding Association Rates and Dissociation Rates Rather Than Binding Affinity27 October 2016 | Bioconjugate Chemistry, Vol. 28, No. 3HIV-1 Entry Inhibitor Resistance25 March 2017Clinical Implications of HIV-1 Drug Resistance21 June 2017Strategy and Tactics for Designing Analogs: Biochemical Characterization of the Large Molecules ☆A comprehensive identification-evidence based alternative for HIV/AIDS treatment with HAART in the healthcare industriesComputer Methods and Programs in Biomedicine, Vol. 131Approved Antiviral Drugs over the Past 50 YearsClinical Microbiology Reviews, Vol. 29, No. 3Decoding protein networks during virus entry by quantitative proteomicsVirus Research, Vol. 218Identification of Peptide Inhibitors of Enveloped Viruses Using Support Vector Machine4 December 2015 | PLOS ONE, Vol. 10, No. 11The HIV-1 Entry Process: A Stoichiometric ViewTrends in Microbiology, Vol. 23, No. 12The C4 region as a target for HIV entry inhibitors - NMR mapping of the interacting segments of T20 and gp12022 October 2015 | FEBS Journal, Vol. 282, No. 24Coevolution Analysis of HIV-1 Envelope Glycoprotein Complex18 November 2015 | PLOS ONE, Vol. 10, No. 11Capacity of Broadly Neutralizing Antibodies to Inhibit HIV-1 Cell-Cell Transmission Is Strain- and Epitope-Dependent9 July 2015 | PLOS Pathogens, Vol. 11, No. 7Small molecule inhibitors of HIVgp41 N-heptad repeat trimer formationBioorganic & Medicinal Chemistry Letters, Vol. 25, No. 14Identification and characterization of a subpocket on the N-trimer of HIV-1 Gp41AIDS, Vol. 29, No. 9Design and characterization of ebolavirus GP prehairpin intermediate mimics as drug targets31 October 2014 | Protein Science, Vol. 24, No. 4Characterization of Potent Fusion Inhibitors of Influenza Virus24 March 2015 | PLOS ONE, Vol. 10, No. 3The Membrane Proximal External Regions of gp41 from HIV-1 Strains HXB2 and JRFL Have Different Sensitivities to Alanine Mutation19 February 2015 | Biochemistry, Vol. 54, No. 8Peptide-Based Inhibitors of Enzymes13 February 2015Peptide fusion inhibitors targeting the HIV-1 gp41: a patent review (2009 – 2014)27 November 2014 | Expert Opinion on Therapeutic Patents, Vol. 25, No. 2Resistance against inhibitors of HIV-1 entry into target cellsFuture Virology, Vol. 10, No. 2Different Infectivity of HIV-1 Strains Is Linked to Number of Envelope Trimers Required for Entry8 January 2015 | PLoS Pathogens, Vol. 11, No. 1Polymeric Anti-HIV Therapeutics3 September 2014 | Macromolecular Bioscience, Vol. 15, No. 1C Peptides as Entry Inhibitors for Gene Therapy12 February 2015Effectiveness of enfuvirtide in a cohort of highly antiretroviral-experienced HIV-1-infected patients in Mexico31 December 2014 | AIDS Research and Therapy, Vol. 11, No. 1Partial rescue of V1V2 mutant infectivity by HIV-1 cell-cell transmission supports the domain's exceptional capacity for sequence variation25 September 2014 | Retrovirology, Vol. 11, No. 1R&D dynamics and scientific breakthroughs in HIV/AIDS drugs development: the case of Integrase Inhibitors28 May 2014 | Scientometrics, Vol. 101, No. 1Peptide entry inhibitors of enveloped viruses: The importance of interfacial hydrophobicityBiochimica et Biophysica Acta (BBA) - Biomembranes, Vol. 1838, No. 9Exposure to Entry Inhibitors Alters HIV Infectiousness and Sensitivity to Broadly Neutralizing Monoclonal AntibodiesJAIDS Journal of Acquired Immune Deficiency Syndromes, Vol. 67, No. 1AIDS: The Final Chapter? Mathilde Krim and Rowena Johnston6 January 2014 | AIDS Research and Human Retroviruses, Vol. 30, No. 1HIV-1 Entry Inhibitor Resistance24 December 2014Rupture of Lipid Vesicles by a Broad-Spectrum Antiviral Peptide: Influence of Vesicle Size9 December 2013 | The Journal of Physical Chemistry B, Vol. 117, No. 50Structure of the Fusion Core and Inhibition of Fusion by a Heptad Repeat Peptide Derived from the S Protein of Middle East Respiratory Syndrome CoronavirusJournal of Virology, Vol. 87, No. 24Bayesian Hierarchical Modeling of the HIV Evolutionary Response to TherapyJournal of the American Statistical Association, Vol. 108, No. 504Lentiviral Vectors for Cancer Immunotherapy and Clinical Applications2 July 2013 | Cancers, Vol. 5, No. 4COMPUTATIONAL STUDY OF HIV-1 gp41 NHR TRIMER: INHIBITION MECHANISMS OF N-SUBSTITUTED PYRROLE DERIVATIVES AND FRAGMENT-BASED VIRTUAL SCREENING12 December 2013 | Journal of Theoretical and Computational Chemistry, Vol. 12, No. 08Interactions of peptide triazole thiols with Env gp120 induce irreversible breakdown and inactivation of HIV-1 virions13 December 2013 | Retrovirology, Vol. 10, No. 1Peptide-Derivatized SB105-A10 Dendrimer Inhibits the Infectivity of R5 and X4 HIV-1 Strains in Primary PBMCs and Cervicovaginal Histocultures7 October 2013 | PLoS ONE, Vol. 8, No. 10An Automated Time-of-Drug-Addition Assay to Routinely Determine the Mode of Action of HIV-1 Inhibitors Marnix Van Loock, Christel Van den Eynde, John Hansen, Peggy Geluykens, Tania Ivens, Sarah Sauviller, Lieve Bunkens, Koen Van Acker, Erik Nijs, and Géry Dams21 October 2013 | ASSAY and Drug Development Technologies, Vol. 11, No. 8A Fusion-Inhibiting Peptide against Rift Valley Fever Virus Inhibits Multiple, Diverse Viruses12 September 2013 | PLoS Neglected Tropical Diseases, Vol. 7, No. 9Analysis and Prediction of Highly Effective Antiviral Peptides Based on Random Forests5 August 2013 | PLoS ONE, Vol. 8, No. 8Antibody and Antiretroviral Preexposure Prophylaxis Prevent Cervicovaginal HIV-1 Infection in a Transgenic Mouse ModelJournal of Virology, Vol. 87, No. 15A Sensitive Assay Using a Native Protein Substrate for Screening HIV-1 Maturation Inhibitors Targeting the Protease Cleavage Site between the Matrix and Capsid11 July 2013 | Biochemistry, Vol. 52, No. 29Development of an HIV-1 Microbicide Based on Caulobacter crescentus: Blocking Infection by High-Density Display of Virus Entry Inhibitors19 June 2013 | PLoS ONE, Vol. 8, No. 6Burkholderia oklahomensis agglutinin is a canonical two-domain OAA-family lectin: structures, carbohydrate binding and anti-HIV activity2 April 2013 | FEBS Journal, Vol. 280, No. 9An ancestral HIV-2/simian immunodeficiency virus peptide with potent HIV-1 and HIV-2 fusion inhibitor activityAIDS, Vol. 27, No. 7HIV-1 envelope glycoprotein structureCurrent Opinion in Structural Biology, Vol. 23, No. 2Short‐peptide fusion inhibitors with high potency against wild‐type and enfuvirtide‐resistant HIV‐111 December 2012 | The FASEB Journal, Vol. 27, No. 3Closing the door to human immunodeficiency virus12 March 2013 | Protein & Cell, Vol. 4, No. 2Recent Advances in Diagnosis, Prevention, and Treatment of Human Respiratory Syncytial VirusAdvances in Virology, Vol. 2013Structure and Function of Respiratory Syncytial Virus Surface Glycoproteins21 December 2013Combating HIV-1 Entry and Fusion with Peptide–Synthetic Polymer Conjugates8 July 2013HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domainBiochimica et Biophysica Acta (BBA) - Biomembranes, Vol. 1818, No. 12Computer-Aided Approaches for Targeting HIVgp4120 August 2012 | Biology, Vol. 1, No. 2Site-Specific PEGylation of HR2 Peptides: Effects of PEG Conjugation Position and Chain Length on HIV-1 Membrane Fusion Inhibition and Proteolytic Degradation25 July 2012 | Bioconjugate Chemistry, Vol. 23, No. 8Computational identification of self-inhibitory peptides from envelope proteins7 June 2012 | Proteins: Structure, Function, and Bioinformatics, Vol. 80, No. 9Small-Molecule Inhibitors of Dengue-Virus Entry5 April 2012 | PLoS Pathogens, Vol. 8, No. 4Cell-Cell Transmission Enables HIV-1 to Evade Inhibition by Potent CD4bs Directed Antibodies5 April 2012 | PLoS Pathogens, Vol. 8, No. 4Highly Active Antiretroviral Therapy for treatment of HIV/AIDS patients: Current status and future prospects and the Indian scenarioHIV & AIDS Review, Vol. 11, No. 1Novel Approaches to Inhibit HIV Entry21 February 2012 | Viruses, Vol. 4, No. 2Development of Anti-HIV Agents Based on Chemical BiologyYAKUGAKU ZASSHI, Vol. 132, No. 1Molecular Mechanisms of HIV Entry8 November 2011Peptide inhibition of human cytomegalovirus infection22 February 2011 | Virology Journal, Vol. 8, No. 1Nonnucleoside Reverse Transcriptase Inhibitor-Resistant HIV Is Stimulated by Efavirenz during Early Stages of InfectionJournal of Virology, Vol. 85, No. 20HIV vs. HIV: Turning HIV‐Derived Peptides into Drugs17 October 2011The successes and failures of HIV drug discovery2 September 2011 | Expert Opinion on Drug Discovery, Vol. 6, No. 10Stabilized helical peptides: overview of the technologies and therapeutic promises22 July 2011 | Expert Opinion on Drug Discovery, Vol. 6, No. 9In vitro inhibition of feline leukaemia virus infection by synthetic peptides derived from the transmembrane domain1 August 2011 | Antiviral Therapy, Vol. 16, No. 6Adoption of an "Open" Envelope Conformation Facilitating CD4 Binding and Structural Remodeling Precedes Coreceptor Switch in R5 SHIV-Infected Macaques8 July 2011 | PLoS ONE, Vol. 6, No. 7Glu659Leu substitution of recombinant HIV fusion inhibitor C52L induces soluble expression in Escherichia coli with equivalent anti-HIV potency7 April 2011 | Protein Engineering Design and Selection, Vol. 24, No. 7Understanding the binding mode and function of BMS-488043 against HIV-1 viral entry4 April 2011 | Proteins: Structure, Function, and Bioinformatics, Vol. 79, No. 6Outlook of the Antiviral Drug Era, Now More Than 50 Years after Description of the First Antiviral Drug12 May 2011A combination of polymorphic mutations in V3 loop of HIV-1 gp120 can confer noncompetitive resistance to maravirocVirology, Vol. 413, No. 2Small molecule HIV entry inhibitors: Part II. Attachment and fusion inhibitors: 2004 – 201023 February 2011 | Expert Opinion on Therapeutic Patents, Vol. 21, No. 3Cell Entry of Enveloped VirusesTargeting the protein–protein interactions of the HIV lifecycle1 January 2011 | Chem. Soc. Rev., Vol. 40, No. 3Peptides that bind the HIV-1 integrase and modulate its enzymatic activity - kinetic studies and mode of action13 December 2010 | FEBS Journal, Vol. 278, No. 2Interface Peptides30 November 2010Inhibition of HIV-1 Entry: Multiple Keys to Close the Door15 September 2010 | ChemMedChem, Vol. 5, No. 11Design of a Potent d -Peptide HIV-1 Entry Inhibitor with a Strong Barrier to ResistanceJournal of Virology, Vol. 84, No. 21GB Virus Type C Envelope Protein E2 Elicits Antibodies That React with a Cellular Antigen on HIV-1 Particles and Neutralize Diverse HIV-1 Isolates8 September 2010 | The Journal of Immunology, Vol. 185, No. 7Identification of a gp41 Core-Binding Molecule with Homologous Sequence of Human TNNI3K-Like Protein as a Novel Human Immunodeficiency Virus Type 1 Entry InhibitorJournal of Virology, Vol. 84, No. 18Design and evaluation of antiretroviral peptides corresponding to the C-terminal heptad repeat region (C-HR) of human immunodeficiency virus type 1 envelope glycoprotein gp41Virology, Vol. 405, No. 1Characterization of HIV-1 resistance to a fusion inhibitor, N36, derived from the gp41 amino-terminal heptad repeatAntiviral Research, Vol. 87, No. 2Structural Optimization and De Novo Design of Dengue Virus Entry Inhibitory Peptides22 June 2010 | PLoS Neglected Tropical Diseases, Vol. 4, No. 65-Modified-2′-dU and 2′-dC as Mutagenic Anti HIV-1 Proliferation Agents: Synthesis and Activity29 January 2010 | Journal of Medicinal Chemistry, Vol. 53, No. 4Twenty-Six Years of Anti-HIV Drug Discovery: Where Do We Stand and Where Do We Go?28 September 2009 | Journal of Medicinal Chemistry, Vol. 53, No. 2Molecular basis of human immunodeficiency virus drug resistance: An updateAntiviral Research, Vol. 85, No. 1Entry inhibitors in the treatment of HIV-1 infectionAntiviral Research, Vol. 85, No. 1Antiretroviral Medications: Adverse Effects on the KidneyAdvances in Chronic Kidney Disease, Vol. 17, No. 1Does enfuvirtide increase the risk of bacterial pneumonia in patients receiving combination antiretroviral therapy?10 November 2009 | Journal of Antimicrobial Chemotherapy, Vol. 65, No. 1Computational approaches to therapeutic peptide discovery19 November 2010 | Biopolymers, Vol. 94, No. 6Long-Lasting Enfuvirtide Carrier Pentasaccharide Conjugates with Potent Anti-Human Immunodeficiency Virus Type 1 ActivityAntimicrobial Agents and Chemotherapy, Vol. 54, No. 1CD4 mimics targeting the mechanism of HIV entryBioorganic & Medicinal Chemistry Letters, Vol. 20, No. 1Bioorganic synthesis of a recombinant HIV-1 fusion inhibitor, SC35EK, with an N-terminal pyroglutamate capping groupBioorganic & Medicinal Chemistry, Vol. 17, No. 23A computational approach identifies two regions of Hepatitis C Virus E1 protein as interacting domains involved in viral fusion process29 July 2009 | BMC Structural Biology, Vol. 9, No. 1Detailed Mechanistic Insights into HIV-1 Sensitivity to Three Generations of Fusion Inhibitors17 July 2009 | Journal of Biological Chemistry, Vol. 284, No. 39The history of antiretrovirals: key discoveries over the past 25 yearsReviews in Medical Virology, Vol. 19, No. 5Combinations of the First and Next Generations of Human Immunodeficiency Virus (HIV) Fusion Inhibitors Exhibit a Highly Potent Synergistic Effect against Enfuvirtide- Sensitive and -Resistant HIV Type 1 StrainsJournal of Virology, Vol. 83, No. 16The Role of Amphiphilicity and Negative Charge in Glycoprotein 41 Interactions in the Hydrophobic Pocket17 June 2009 | Journal of Medicinal Chemistry, Vol. 52, No. 14HIV entry inhibitors and their potential in HIV therapyMedicinal Research Reviews, Vol. 29, No. 2Basic Residues Are Critical to the Activity of Peptide Inhibitors of Human T Cell Leukemia Virus Type 1 EntryJournal of Biological Chemistry, Vol. 284, No. 10SC29EK, a Peptide Fusion Inhibitor with Enhanced α-Helicity, Inhibits Replication of Human Immunodeficiency Virus Type 1 Mutants Resistant to EnfuvirtideAntimicrobial Agents and Chemotherapy, Vol. 53, No. 3Designed recombinant adenovirus type 5 vector induced envelope-specific CD8 + cytotoxic T lymphocytes and cross-reactive neutralizing antibodies against human immunodeficiency virus type 1The Journal of Gene Medicine, Vol. 11, No. 2Clinical Implications of HIV-1 Drug ResistanceIntracellular Membrane FusionResistance to Enfuvirtide and Other HIV Entry InhibitorsCharacterization of the steric defense of the HIV‐1 gp41 N‐trimer region2 January 2009 | Protein Science, Vol. 17, No. 12Highly specific inhibition of leukaemia virus membrane fusion by interaction of peptide antagonists with a conserved region of the coiled coil of envelope4 August 2008 | Retrovirology, Vol. 5, No. 1Conserved Salt Bridge between the N- and C-Terminal Heptad Repeat Regions of the Human Immunodeficiency Virus Type 1 gp41 Core Structure Is Critical for Virus Entry and InhibitionJournal of Virology, Vol. 82, No. 22Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains21 October 2008 | Proceedings of the National Academy of Sciences, Vol. 105, No. 42Update on the development of HIV entry inhibitorsFuture HIV Therapy, Vol. 2, No. 5HIV-1 envelope glycoprotein-mediated fusion and pathogenesis: Implications for therapy and vaccine developmentVaccine, Vol. 26, No. 24Productive infection of human immunodeficiency virus type 1 in dendritic cells requires fusion-mediated viral entryVirology, Vol. 375, No. 2Importance of the Membrane-Perturbing Properties of the Membrane-Proximal External Region of Human Immunodeficiency Virus Type 1 gp41 to Viral FusionJournal of Virology, Vol. 82, No. 11Immunologic Benefits of Enfuvirtide in Patients Enrolled in a Drug Assistance Program15 April 2008 | Annals of Pharmacotherapy, Vol. 42, No. 5Design of an engineered N-terminal HIV-1 gp41 trimer with enhanced stability and potencyProtein Science, Vol. 17, No. 4The function of coreceptor as a basis for the kinetic dissection of HIV type 1 envelope protein‐mediated cell fusion21 November 2007 | The FASEB Journal, Vol. 22, No. 4Coronavirus Escape from Heptad Repeat 2 (HR2)-Derived Peptide Entry Inhibition as a Result of Mutations in the HR1 Domain of the Spike Fusion ProteinJournal of Virology, Vol. 82, No. 5Peptide Mimic of the HIV Envelope gp120–gp41 InterfaceJournal of Molecular Biology, Vol. 376, No. 3Relative concordance of human immunodeficiency virus oligomeric and monomeric envelope in CCR5 coreceptor usageVirology, Vol. 370, No. 2Resistance to Neutralization by Antibodies Targeting the Coiled Coil of Fusion-active Envelope Is a Common Feature of RetrovirusesJournal of Biological Chemistry, Vol. 282, No. 50A Covalent Inhibitor Targeting an Intermediate Conformation of the Fusogenic Subunit of the HIV-1 Envelope Complex28 August 2007 | Journal of Biological Chemistry, Vol. 282, No. 44Demonstrating the C‐terminal boundary of the HIV 1 fusion conformation in a dynamic ongoing fusion process and implication for fusion inhibition15 June 2007 | The FASEB Journal, Vol. 21, No. 13Characterization of Human Immunodeficiency Virus Type 1 Replication in Immature and Mature Dendritic Cells Reveals Dissociable cis - and trans -InfectionJournal of Virology, Vol. 81, No. 20Safety and Efficacy of Enfuvirtide for 48 Weeks as Part of an Optimized Antiretroviral Regimen in Pediatric Human Immunodeficiency Virus 1-Infected PatientsPediatric Infectious Disease Journal, Vol. 26, No. 9Formation and Reversible Dissociation of Coiled Coil of Peptide to the C-Terminus of the HSV B5 Protein: A Time-Resolved Spectroscopic AnalysisBiophysical Journal, Vol. 93, No. 3Human Immunodeficiency Virus Type 1 Variants Resistant to First- and Second-Version Fusion Inhibitors and Cytopathic in Ex Vivo Human Lymphoid TissueJournal of Virology, Vol. 81, No. 12Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adultsAIDS, Vol. 21, No. 10Population Pharmacokinetics of Enfuvirtide in HIV-1-Infected Pediatric Patients Over 48 Weeks of Treatment8 March 2013 | The Journal of Clinical Pharmacology, Vol. 47, No. 4HIV-1 gp41 heptad repeat 2 (HR2) possesses an amino acid domain that resembles the allergen domain in Aspergillus fumigatus Asp f1 protein: review, hypothesis and implications1 March 2007 | Virus Genes, Vol. 34, No. 3Role of envelope processing and gp41 membrane spanning domain in the formation of human immunodeficiency virus type 1 (HIV-1) fusion–competent envelope glycoprotein complexVirus Research, Vol. 124, No. 1-2Membrane Perturbing Actions of HIV Type 1 Glycoprotein 41 Domains Are Inhibited by Helical C-Peptides Patrick W. Mobley, Jay A. Barry, Alan J. Waring, Mark A. Sherman, and Larry M. Gordon1 March 2007 | AIDS Research and Human Retroviruses, Vol. 23, No. 2Therapeutic potential of the chemokine receptor CXCR4 antagonists as multifunctional agents1 January 2007 | Biopolymers, Vol. 88, No. 2Enfuvirtide: from basic science to FDA approvalTargets for drug development — past and presentFunctional and Structural Characterization of HIV-1 gp41 Ectodomain Regions in Phospholipid Membranes Suggests that the Fusion-active Conformation Is ExtendedJournal of Molecular Biology, Vol. 364, No. 5Pharmacokinetic Bioequivalence of Enfuvirtide Using a Needle-Free Device versus Standard Needle AdministrationPharmacotherapy, Vol. 26, No. 12Functions of the Stem Region of the Semliki Forest Virus Fusion Protein during Virus Fusion and AssemblyJournal of Virology, Vol. 80, No. 22A Prospective Clinical and Pathological Examination of Injection Site Reactions with the HIV-1 Fusion Inhibitor Enfuvirtide1 October 2006 | Antiviral Therapy, Vol. 11, No. 7Small molecules that bind the inner core of gp41 and inhibit HIV envelope-mediated fusion19 September 2006 | Proceedings of the National Academy of Sciences, Vol. 103, No. 38Identification of the HIV-1 gp41 core-binding motif - HXXNPF4 August 2006 | FEBS Letters, Vol. 580, No. 20Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike proteinVirus Research, Vol. 120, No. 1-2Supporting Basic Research: Discovering a New Class of Anti-HIV Drug Carl Wild13 July 2006 | AIDS Patient Care and STDs, Vol. 20, No. 7θ-Defensins Prevent HIV-1 Env-mediated Fusion by Binding gp41 and Blocking 6-Helix Bundle FormationJournal of Biological Chemistry, Vol. 281, No. 27Characterization of Envelope Glycoprotein gp41 Genotype and Phenotypic Susceptibility to Enfuvirtide at Baseline and on Treatment in the Phase III Clinical Trials TORO-1 and TORO-2 T. Melby, P. Sista, R. DeMasi, T. Kirkland, N. Roberts, M. Salgo, G. Heilek-Snyder, N. Cammack, T.J. Matthews, and M.L. Greenberg17 May 2006 | AIDS Research and Human Retroviruses, Vol. 22, No. 5Progress in identifying peptides and small-molecule inhibitors targeted to gp41 of HIV-124 April 2006 | Expert Opinion on Investigational Drugs, Vol. 15, No. 5HIV entry inhibitors: mechanisms of action and resistance pathways7 February 2006 | Journal of Antimicrobial Chemotherapy, Vol. 57, No. 4Structurally Altered Peptides Reveal an Important Role for N-terminal Heptad Repeat Binding and Stability in the Inhibitory Action of HIV-1 Peptide DP178Journal of Biological Chemistry, Vol. 281, No. 14Membrane-Anchored Inhibitory Peptides Capture Human Immunodeficiency Virus Type 1 gp41 Conformations That Engage the Target Membrane prior to FusionJournal of Virology, Vol. 80, No. 7Entrada del virus de la inmunodeficiencia humana en las células: mecanismos y posibilidades terapéuticasMedicina Clínica, Vol. 126, No. 9Therapeutic innovations against HIV28 February 2006 | Expert Opinion on Therapeutic Patents, Vol. 16, No. 3Highly Potent and Orally Active CCR5 Antagonists as Anti-HIV-1 Agents: Synthesis and Biological Activities of 1-Benzazocine Derivatives Containing a Sulfoxide Moiety1 March 2006 | Journal of Medicinal Chemistry, Vol. 49, No. 6Pharmacokinetics, pharmacodynamics and safety of once-daily versus twice-daily dosing with enfuvirtide in HIV-infected subjectsAIDS, Vol. 20, No. 3Long-term monitoring of genotypic and phenotypic resistance to T20 in treated patients infected with HIV-11 January 2005 | Journal of Medical Virology, Vol. 78, No. 2Class II virus membrane fusion proteinsVirology, Vol. 344, No. 1Direct Fmoc/ tert -Bu solid phase synthesis of octamannosyl polylysine dendrimer-peptide conjugatesBiopolymers, Vol. 84, No. 2T-cell line for HIV drug screening using EGFP as a quantitative marker of HIV-1 replicationBioTechniques, Vol. 40, No. 1Virus membrane-fusion proteins: more than one way to make a hairpinNature Reviews Microbiology, Vol. 4, No. 1Bioengineering Lactic Acid Bacteria to Secrete the HIV-1 Virucide CyanovirinJAIDS Journal of Acquired Immune Deficiency Syndromes, Vol. 40, No. 5Durable Efficacy of Enfuvirtide Over 48 Weeks in Heavily Treatment-Experienced HIV-1-Infected Patients in the T-20 Versus Optimized Background Regimen Only 1 and 2 Clinical TrialsJAIDS Journal of Acquired Immune Deficiency Syndromes, Vol. 40, No. 4Peptide inhibitors of dengue virus and West Nile virus infectivity1 June 2005 | Virology Journal, Vol. 2, No. 1Efficient trapping of HIV-1 envelope protein by hetero-oligomerization with an N-helix chimera10 August 2005 | Retrovirology, Vol. 2, No. 1Cell Death in HIV Infection13 January 2010Inhibition of HIV-1 group M and O isolates by fusion inhibitorsAIDS, Vol. 19, No. 16Alterations of lymphocyte membrane